STAMFORD, Conn., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. Bilenker , M.D., chief executive officer, will present a corporate overview at three upcoming conferences.

Details of the conferences are as follows:
  • Stifel 2015 Healthcare Conference, November 17, 2015 at 4:30 pm Eastern Time, Lotte New York Palace, New York, NY
  • Piper Jaffray 27 th Annual Healthcare Conference, December 1, 2015 at 8:00 am Eastern Time, Lotte New York Palace, New York, NY
  • Oppenheimer 26 th Annual Healthcare Conference, December 9, 2015 at 2:10 pm Eastern Time, Westin New York Grand Central, New York, NY

Live webcasts of the presentations will be available at http://ir.loxooncology.com/.

About Loxo Oncology

Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.

Contacts for Loxo Oncology, Inc.Company:Jacob S. Van NaardenVice President, Corporate Development and Strategy jake@loxooncology.com

Investors:Peter RahmerThe Trout Group, LLC646-378-2973 prahmer@troutgroup.com

Media:Dan BudwickPure Communications, Inc.973-271-6085 dan@purecommunicationsinc.com